NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
NeOnc Technologies scheduled an investor conference call for August 12, 2026, to present topline results from the Phase 2a portion of the NEO100-01 clinical trial. The study evaluated intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.
Key figures
- Drug Name
- NEO100
- Phase Of Trial
- Phase 2a
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.